What Researchers Did
Researchers conducted a double-blind, randomized, placebo-controlled trial on 37 middle-aged master athletes to evaluate the effects of 40 sessions of hyperbaric oxygen therapy (HBOT) on physical performance and mitochondrial function.
What They Found
Following hyperbaric oxygen therapy (HBOT), there was a significant increase in maximal oxygen consumption (VO2Max) (p=0.010, effect size=0.989) and oxygen consumption at the anaerobic threshold (effect size=0.837) compared to the SHAM group. HBOT also led to significant increases in maximal oxygen phosphorylation capacity (effect size=1.085, p=0.04), maximal uncoupled capacity (effect size=0.956, p=0.02), and mitochondrial mass marker MTG (p=0.0002).
What This Means for Canadian Patients
Hyperbaric oxygen therapy (HBOT) may offer a potential method for middle-aged Canadian athletes to enhance their physical performance and improve mitochondrial function. While promising, individuals should consult healthcare professionals before considering such therapies, as the study focused on a specific athletic population.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or participants.
Study Limitations
A limitation of this study is its relatively small sample size and focus on a specific population of healthy middle-aged master athletes, which may limit generalizability.